Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rossiter

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
ACS Infectious Diseases|April 15, 2020
Target-Based Design of Promysalin Analogues Identifies a New Putative Binding Cleft in Succinate DehydrogenaseSavannah J Post, Colleen E Keohane, Lauren M Rossiter, et al.
ACS Infectious Diseases|July 8, 2022
Correction to "Target-Based Design of Promysalin Analogs Identifies a New Putative Binding Cleft in Succinate Dehydrogenase"Savannah J Post, Colleen E Keohane, Lauren M Rossiter, et al.
Journal of Consulting and Clinical Psychology|April 1, 1993
Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: a controlled comparisonD E Wilfley, W S Agras, C F Telch, et al.
The American Journal of Psychiatry|January 1, 1992
Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparisonW S Agras, E M Rossiter, B Arnow, et al.
Psychiatry Research|September 8, 1995
Comparing the cost effectiveness of psychiatric treatments: bulimia nervosaL M Koran, W S Agras, E M Rossiter, et al.
Scientific Reports|August 25, 2017
Light-Triggered Soft Artificial Muscles: Molecular-Level Amplification of Actuation Control SignalsMichael P M Dicker, Anna B Baker, Robert J Iredale, et al.
Neurology|August 8, 2007
Paroxysmal extreme pain disorder (previously familial rectal pain syndrome)C R Fertleman, C D Ferrie, J Aicardi, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate CancerAaron Balog, Richard Rampulla, Gregory S Martin, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2010
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonistsHai-Yun Xiao, Aaron Balog, Ricardo M Attar, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
ACS Infectious Diseases|April 15, 2020
Target-Based Design of Promysalin Analogues Identifies a New Putative Binding Cleft in Succinate DehydrogenaseSavannah J Post, Colleen E Keohane, Lauren M Rossiter, et al.
ACS Infectious Diseases|July 8, 2022
Correction to "Target-Based Design of Promysalin Analogs Identifies a New Putative Binding Cleft in Succinate Dehydrogenase"Savannah J Post, Colleen E Keohane, Lauren M Rossiter, et al.
Journal of Consulting and Clinical Psychology|April 1, 1993
Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: a controlled comparisonD E Wilfley, W S Agras, C F Telch, et al.
The American Journal of Psychiatry|January 1, 1992
Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparisonW S Agras, E M Rossiter, B Arnow, et al.
Psychiatry Research|September 8, 1995
Comparing the cost effectiveness of psychiatric treatments: bulimia nervosaL M Koran, W S Agras, E M Rossiter, et al.
Scientific Reports|August 25, 2017
Light-Triggered Soft Artificial Muscles: Molecular-Level Amplification of Actuation Control SignalsMichael P M Dicker, Anna B Baker, Robert J Iredale, et al.
Neurology|August 8, 2007
Paroxysmal extreme pain disorder (previously familial rectal pain syndrome)C R Fertleman, C D Ferrie, J Aicardi, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate CancerAaron Balog, Richard Rampulla, Gregory S Martin, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2010
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonistsHai-Yun Xiao, Aaron Balog, Ricardo M Attar, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
Pageof 7